EPISODE · Jun 24, 2025 · 12 MIN
ASCO 2025 Plenary: SERENA-6
from Two Onc Docs
This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer.We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.
Embed this episode
NOW PLAYING
ASCO 2025 Plenary: SERENA-6
0:00
12:33
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Two Onc Docs?
This episode is 12 minutes long.
When was this Two Onc Docs episode published?
This episode was published on June 24, 2025.
Can I download this Two Onc Docs episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!